On September 26, 2016 Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, reported a collaboration under which sites affiliated with US Oncology Research will participate in the FOCUS Study, Mateon’s recently initiated phase 2/3 clinical trial in platinum-resistant ovarian cancer (Press release, Mateon Therapeutics, SEP 26, 2016, View Source [SID:SID1234515403]). Schedule your 30 min Free 1stOncology Demo! "We are pleased to work with US Oncology Research, an outstanding organization that has had tremendous success in oncology-related clinical trials," stated William D. Schwieterman, M.D., President and Chief Executive Officer of Mateon. "US Oncology Research is selective regarding the studies in which it participates. So we are pleased they recognize the importance of developing CA4P for women with platinum-resistant ovarian cancer."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
US Oncology Research is a premier organization in the United States dedicated to bringing physicians, clinics and patients together for innovative cancer research in the community setting. One of the largest community-based oncology research programs in the U.S., US Oncology Research has nearly 150 affiliated locations as well as more than 900 affiliated investigators. The organization has played a role in the development of more than 60 FDA-approved cancer therapies, which represents about one-third of all cancer therapies approved by the FDA to date, and manages about 300 active clinical trials at any given time.
"Inhibition of tumor-related angiogenesis provides an important therapeutic option for women with recurrent ovarian cancer," stated Michael A. Bookman, M.D., Director, Gynecologic Oncology Research, US Oncology Research. "Strategies to combine Mateon’s CA4P, a novel vascular disrupting agent, with other agents, including bevacizumab, appear promising, and we are excited to offer our patients the opportunity to participate in this high-priority randomized trial."
About FOCUS
The FOCUS Study is a randomized, double-blind, 2-arm, parallel-group, phase 2/3 study to evaluate the efficacy and safety of physician’s choice chemotherapy (PCC) plus bevacizumab and CA4P versus PCC plus bevacizumab in patients with platinum-resistant ovarian cancer. The primary endpoint of the FOCUS Study is progression free survival (PFS). The Study will also evaluate CA4P’s effect on objective response rate (ORR), overall survival (OS) and other parameters. For additional information on the FOCUS Study, please visit www.clinicaltrials.gov, study identifier NCT02641639.